AzTrials
AzTrials

ConstipationNCT02395484

Metagenome Analysis of Gut Microbiota in CC Patients

An observational study of Constipation, run by Jinling Hospital, China at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Constipation is a heterogeneous and multifactorial disease, influenced by a number of different genetic and environmental factors. By applying the standard two-stage GWAS strategy to design and carry out a metagenome-wide association study (MGWAS) to find the relationship between gut microbiota and constipation, to… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Constipation
How many people
50 participants
Where
1 siteChina
Study dates
Mar 2015to Jun 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: 50 faecal samples were obtained from constipation patients and 50 faecal samples were obtained from healthy volunteers

Who may be able to join

  • Chronic constipation according to Rome III criteria;
  • Age ≥ 18 years;
  • BMI: 18.5-25kg/m2;

Who cannot join

  • Bowel constipation due to innate factor (e.g. megacolon) or secondary interventions (e.g. drugs, endocrine, metabolic, neurologic or psychologic disorders);
  • History or evidence of gastrointestinal diseases (e.g. cancer, inflammatory bowel diseases);
  • Previous abdominal surgery, except cholecystectomy, appendicectomy, tubal ligation and cesarean section;
  • Previous proctological or perianal surgery;
  • Rectal prolapse and/or grade 3-4 internal hemorrhoids according to AGA classification;
  • A constipation condition meeting the Rome III criteria for IBS or functional abdominal pain syndrome;
Show all 12Show fewer
  • Pregnant or breast-feeding women;
  • Infection with enteric pathogen;
  • Usage of probiotics, prebiotics, antibiotics or PPIs within the last month;
  • Smoking or alcohol addiction within the last 3 months;
  • Uncontrolled hepatic, renal, cardiovascular, respiratory or psychiatric disease;
  • Disease or therapy with drugs (e.g. antidepressants, opioid narcotic analgesics, anticholinergics, calcium antagonists, nitrates, antimuscarinics) that, in the opinion of the investigator, could affect intestinal transit and microbiota.

Trial locations and contacts

1 site in 1 country.

China1 site, 1 recruiting
  • Jinling Hospital

    Nanjing, Jiangsu, 210000

    Ning Li, MD, +86-25-80860089, jinlingh_lining@126.com

    Recruiting

Other trials in China

About this study

Official title: Species and Metagenome Analysis of Gut Microbiota in Chronic Constipation Patients

Constipation is a heterogeneous and multifactorial disease, influenced by a number of different genetic and environmental factors. By applying the standard two-stage GWAS strategy to design and carry out a metagenome-wide association study (MGWAS) to find the relationship between gut microbiota and constipation, to identify disease-associated metagenomic markers.

Read the detailed description

This study is a two-stage case-control metagenome-wide association study (MGWAS) based on deep next-generation shotgun sequencing of DNA extracted from the stool samples from a total of 50 Chinese constipation patients and healthy controls.

Conditions
Constipation
Medical subject headings
Constipation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02395484
Study groupRoleWhat they receive
constipationcollect stool samples from constipation patients
healthy controlscollect stool samples from healthy controls patients

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. taxonomic and functional characterization of gut microbiota

    Measured: one year

Secondary outcomes (2)
  1. Gut-microbiota-based constipation classification

    Measured: one year

  2. constipation-associated gut microbial markers

    Measured: one year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Mar 2015 (estimated)
  2. Study startMar 2015
  3. Primary completionMar 2016 (estimated)
  4. Study completionJun 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Ecologic or community
Time perspective
Prospective
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02395484
Sponsor's protocol ID
MetagenomeNanjing
Status last verified
May 2015
First submitted
17 Mar 2015
Last updated
4 May 2015
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Constipation, run by Jinling Hospital, China at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 May 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ning Li, MD (+86-25-80860089, jinlingh_lining@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

taxonomic and functional characterization of gut microbiota (time frame: one year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in